Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Intensity Therapeutics, Inc.
NextCure, Inc.
Essen Biotech
Augusta University
Kineta Inc.
H. Lee Moffitt Cancer Center and Research Institute